VENICE, FL--(Marketwire - July 15, 2008) - On the heels of the recent announcement stating a commitment to develop a product to attack MRSA -- the so-called “super bug,” SinoFresh HealthCare, Inc. (OTCBB: SFSH) announced today the continuation of a series of development activities to implement that commitment. This is a study, which will be in the lab phase by the end of July 2008, and according to Dr. John Todhunter, an outside consultant to SinoFresh, “is expected to give robust proof of concept for the nasal formulation designed to kill MRSA hiding in the nose.”
